Search For

CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway

Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors

Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance

Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells

Resistance signatures manifested in early drug response across cancer types and species

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer

IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer